Lung Transplant Recipients Have High Secretory Phospholipase A2 Levels in the Alveoli: First Insight into a Possible Silent Inflammatory Pattern

Purpose: Survival after lung transplantation is limited by the development of chronic lung allograft dysfunction (CLAD). Inflammation is a driving force in the process leading to CLAD and one of CLAD main features. Several lung inflammatory diseases, including acute lung injury, acute respiratory distress syndrome, asthma, and meconium aspiration syndrome show an increased level of the secretory phospholipase A2 type IIA (sPLA2-IIA) enzyme. sPLA2 is mainly expressed following inflammatory or bacterial stimuli and hydrolyzes membrane and surfactant phospholipids, causing lipidome alteration and the production of arachidonic acid metabolites.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research